Related Experiment Video
Updated: Apr 23, 2026
Rapid in vivo Drug Response Prediction Using Leukemia Cell Grafts in Zebrafish Embryos
Published on: May 23, 2025
Focused chemical genomics using zebrafish xenotransplantation as a pre-clinical therapeutic platform for T-cell acute
Victoria L Bentley1, Chansey J Veinotte2, Dale P Corkery3
1Pathology, Dalhousie University, Halifax, NS.
Abstract:
Cancer therapeutics is evolving to precision medicine, with the goal of matching targeted compounds with molecular aberrations underlying a patient's cancer. While murine models offer a pre-clinical tool, associated costs and time are not compatible with actionable patient-directed interventions. Using the paradigm of T-cell acute lymphoblastic leukemia, a high-risk disease with defined molecular underpinnings, we developed a zebrafish human cancer xenotransplantation model to inform therapeutic decisions. Using a focused chemical genomic approach, we demonstrate that xenografted cell lines harboring mutations in the NOTCH1 and PI3K/AKT pathways respond concordantly to their targeted therapies, patient-derived T-cell acute lymphoblastic leukemia can be successfully engrafted in zebrafish and specific drug responses can be quantitatively determined. Using this approach, we identified a mutation sensitive to γ-secretase inhibition in a xenograft from a child with T-cell acute lymphoblastic leukemia, confirmed by Sanger sequencing and validated as a gain-of-function NOTCH1 mutation. The zebrafish xenotransplantation platform provides a novel cost-effective means of tailoring leukemia therapy in real time.
Insights
A novel zebrafish xenotransplantation model enables rapid, cost-effective testing of cancer therapeutics. This precision medicine approach identifies effective drug responses for T-cell acute lymphoblastic leukemia patients in real time.
Area of Science:
- Oncology
- Genetics
- Pharmacology
Background:
- Precision medicine aims to match targeted therapies with specific cancer mutations.
- Current preclinical models like murine models are time-consuming and costly for patient-directed therapy.
- T-cell acute lymphoblastic leukemia (T-ALL) is a high-risk cancer with known molecular drivers.
Purpose of the Study:
- To develop a zebrafish human cancer xenotransplantation model for T-ALL.
- To assess the feasibility of using this model to guide therapeutic decisions in real time.
- To evaluate the efficacy of targeted therapies based on specific genetic mutations.
Main Methods:
- Developed a zebrafish xenotransplantation model for human T-ALL.
- Employed a chemical genomic approach to test drug responses in xenografted cells.
- Utilized Sanger sequencing to confirm genetic mutations, including NOTCH1 gain-of-function.
Main Results:
- Zebrafish xenografts of T-ALL cell lines showed concordant responses to targeted therapies for NOTCH1 and PI3K/AKT pathway mutations.
- Patient-derived T-ALL cells were successfully engrafted and drug responses quantitatively determined in zebrafish.
- Identified a specific mutation sensitive to gamma-secretase inhibition in a pediatric T-ALL xenograft.
Conclusions:
- The zebrafish xenotransplantation platform offers a cost-effective alternative to murine models for preclinical cancer research.
- This model can inform personalized leukemia therapy by providing real-time drug response data.
- Demonstrated the potential of zebrafish xenografts for advancing precision oncology.
